Pharma Pulse 2/17/25: Strategies for Addressing Unmet Needs in Women’s Health, The Future of Personalized Medicine & more
The latest news for pharma industry insiders.
The Future of Personalized Medicine
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, shares how the development of technology will help bolster the pharma logistics industry.
Strategies for Addressing Unmet Needs in Women’s Health and Supporting Women During Menopause
Panelists discuss how menopause marks a significant life transition, characterized by hormonal decline, reproduction cessation, and unique physiological changes requiring medical and emotional support. Health care professionals guide women through life’s reproductive stages, providing comprehensive health care from menarche to post menopause, focusing on individualized prevention of symptom management, and holistic well-being across hormonal transitions.
What RFK Jr.'s New Power Means for Vaccines, Weight-Loss Shots and Drug Ads
Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.
Nexus Pharmaceuticals Receives FDA Approval for Tacrolimus Injection
Nexus Pharmaceuticals, LLC announces the U.S Food and Drug Administration (FDA) approval of Tacrolimus Injection 5 mg/mL. Nexus’ Tacrolimus Injection is the first and only vial that will be available.
Teva Pharmaceuticals on LinkedIn
“When I got here, everybody said Teva is a generics company. I said, I don’t think it is. When I looked under the hood, I saw this innovation - some launched, some in the pipeline - and then I saw this world-class generics business. I said, this is a pharma company that does both.”
Our CEO, Richard Francis, sat down with Pharmaceutical Executive for the publication’s February issue to share his insights on Teva’s progress across the four key pillars of our Pivot to Growth strategy and the significant advancements Teva made in 2024.
Richard emphasizes our organization’s commitment to innovation and sustainable growth, sharing a roadmap on where our organization is heading in 2025 and beyond.
Check out the full interview from Pharma Exec here: https://ow.ly/BGkz50UZi2c
#Tevapharm #PivottoGrowth #Innovation
Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs
Social Media's Influence on Young Women's Reproductive Decisions
February 20th 2025In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 18th 2025Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
